Distal perfusion catheter insertion
ProcedureDistal perfusion catheter insertion under fluoroscopy or ultrasouond guidance in ipsilateral femoral artery to prevent limb ischemia.
Other names: DPC insertion
NCT Number: NCT07482865
A prospective, multi-center, open label, randomized controlled, superiority trial to compare clinical outcomes between routine distal perfusion catheter (DPC) insertion versus provisional distal perfusion catheter (DPC) insertion in the occurrence of sign or symptom of acute limb ischemia in patients undergoing mechanical circulatory support (MCS) through femoral artery approach.
Trial opening soon.
Get Notified19 year and older
All sexes
Interventional
Not applicable
Gyeongsang National University Changwon Hospital, Changwon, South Korea
Acute limb ischemia is a well-recognized vascular complication following peripheral mechanical circulatory support (MCS) including veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or a percutaneous microaxial ventricular assist device (Impella) via femoral arterial cannulation, with reported incidence rates ranging up to 10-30% of patients. Distal perfusion catheter (DPC) has been introduced as a strategy to restore antegrade flow distal to the femoral arterial cannula, aiming to mitigate ischemic complications by augmenting perfusion through antegrade flow into the superficial femoral artery.
Current practice guidance from the Extracorporeal Life Support Organization (ELSO) supports the use of ipsilateral DPC placement at the time of peripheral VA-ECMO cannulation to reduce the risk of limb ischemia and recommends monitoring for adequate flow using Doppler or near-infrared spectroscopy (NIRS). However, these recommendations are predominantly based on observational studies and expert consensus, and do not stem from randomized controlled trial evidence. Current expert consensus and related guidelines describe that routine prophylactic DPC insertion should be considered in patients undergoing VA-ECMO as Class IIa (Level of evidence B) recommendation.
Several observational cohort studies have associated routine prophylactic DPC with reduced limb ischemia compared with no DPC placement, yet these are limited by confounding bias and variability in clinical practice patterns. Retrospective data suggested that delayed or rescue insertion after onset of limb ischemia may be less effective at preventing major ischemic sequelae than earlier DPC insertion strategies.
Given the absence of robust evidence from randomized controlled trial, it remains uncertain whether a strategy of routine prophylactic DPC insertion would be superior over a provisional DPC insertion guided by clinical monitoring in terms of limb ischemia reduction, limb-related morbidity, duration of MCS, and other clinical outcomes including in-hospital mortality.
In this regard, Routine versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support (PERFUSE-MCS) trial was designed to compare clinical outcomes between routine DPC insertion versus provisional DPC insertion in the occurrence of sign or symptom of acute limb ischemia in patients undergoing MCS through femoral artery approach.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Distal perfusion catheter insertion under fluoroscopy or ultrasouond guidance in ipsilateral femoral artery to prevent limb ischemia.
Other names: DPC insertion
Time frame: within 30 days from randomization
Major limb ischemia requiring intervention
Time frame: within 90 days from randomization
Time to all-cause mortality
Time frame: within 90 days from randomization
Time to cardiovascular mortality
Time frame: within 90 days from randomization
Successful weaning of mechanical circulatory device
Time frame: within 90 days from randomization
Bleeding defined by BARC type 2,3, or 5
Time frame: within 90 days from randomization
Systemic thromboembolism other than stroke during MCS
Time frame: within 90 days from randomization
Cerebrovascular accidents (ischemic stroke or hemorrhagic stroke)
Time frame: within 30 days from randomization
Rates of renal replacement therapy during index hospitalization
Time frame: within 30 days from randomization
Duration of MCS during index hospitalization
Time frame: within 30 days from randomization
Duration of hospital stay during index hospitalization
Time frame: within 30 days from randomization
Duration of mechanical ventilation during index hospitalization
Contact information is provided by the study sponsor or research team.
Jeong Hoon Yang, MD, PhD
CONTACT
Joo Myung Lee, MD, MPH, PhD
CONTACT
Samsung Medical Center
Other
Acronym: PERFUSE-MCS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07601828
Cardiogenic Shock, Cardiovascular Diseases
View Trial DetailsNCT06965504
Cardiogenic Shock, Cardiovascular Diseases
Tampa, Florida, United States
View Trial DetailsNCT07461961
Cardiogenic Shock, Cardiovascular Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07163052
Cardiogenic Shock, Cardiovascular Diseases
View Trial Details